PMID- 22843556
OWN - NLM
STAT- MEDLINE
DCOM- 20130121
LR  - 20220309
IS  - 1479-6821 (Electronic)
IS  - 1351-0088 (Linking)
VI  - 19
IP  - 5
DP  - 2012 Oct
TI  - Diabetes and pancreatic cancer.
PG  - F9-F26
LID - 10.1530/ERC-12-0105 [doi]
AB  - Epidemiological studies clearly indicate that the risk of pancreatic cancer (PC) 
      is increased in diabetic patients, but most studies focus on overall diabetes or 
      type 2 diabetes mellitus (T2DM), and there are few studies on the risks of type 1 
      and type 3c (secondary) diabetes. Possible mechanisms for increased cancer risk 
      in diabetes include cellular proliferative effects of hyperglycemia, 
      hyperinsulinemia, and abnormalities in insulin/IGF receptor pathways. Recently, 
      insulin and insulin secretagogues have been observed to increase the PC risk, 
      while metformin treatment reduces the cancer risk in diabetic subjects. In 
      addition, anticancer drugs used to treat PC may either cause diabetes or worsen 
      coexisting diabetes. T3cDM has emerged as a major subset of diabetes and may have 
      the highest risk of pancreatic carcinoma especially in patients with chronic 
      pancreatitis. T3cDM is also a consequence of PC in at least 30% of patients. 
      Distinguishing T3cDM from the more prevalent T2DM among new-onset diabetic 
      patients can be aided by an assessment of clinical features and confirmed by 
      finding a deficiency in postprandial pancreatic polypeptide release. In 
      conclusion, diabetes and PC have a complex relationship that requires more 
      clinical attention. The risk of developing PC can be reduced by aggressive 
      prevention and treatment of T2DM and obesity and the prompt diagnosis of T3cDM 
      may allow detection of a tumor at a potentially curable stage.
FAU - Cui, YunFeng
AU  - Cui Y
AD  - Department of Surgery, Johns Hopkins Bayview Medical Center, Johns Hopkins 
      University School of Medicine, Baltimore, Maryland, USA.
FAU - Andersen, Dana K
AU  - Andersen DK
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20120905
PL  - England
TA  - Endocr Relat Cancer
JT  - Endocrine-related cancer
JID - 9436481
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin)
RN  - 9100L32L2N (Metformin)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/adverse effects
MH  - *Diabetes Complications
MH  - Diabetes Mellitus/drug therapy/etiology
MH  - Humans
MH  - Hypoglycemic Agents/adverse effects
MH  - Insulin/adverse effects
MH  - Metformin/adverse effects
MH  - Obesity/complications
MH  - Pancreatic Neoplasms/drug therapy/*etiology
MH  - Risk Factors
EDAT- 2012/07/31 06:00
MHDA- 2013/01/23 06:00
CRDT- 2012/07/31 06:00
PHST- 2012/07/31 06:00 [entrez]
PHST- 2012/07/31 06:00 [pubmed]
PHST- 2013/01/23 06:00 [medline]
AID - ERC-12-0105 [pii]
AID - 10.1530/ERC-12-0105 [doi]
PST - epublish
SO  - Endocr Relat Cancer. 2012 Sep 5;19(5):F9-F26. doi: 10.1530/ERC-12-0105. Print 
      2012 Oct.